Clinical significance of co-expression of CD21 and LFA-1 in B-cell lymphoma.
We previously reported that the prognosis of CD21-positive diffuse large B-cell lymphoma (DLBCL) is significantly favorable to that of CD21-negative DLBCL (Otsuka et al. in Br J Haematol 127:416-424, 2004). In this study, we attempted to clarify the biological significance of CD21 expression in B-cell lymphoma (BCL) by performing in vitro experiments using CD21 transfection into a CD21-negative lymphoma cell line and analyzing clinical data from lymphoma samples. Established clones of CD21 transfectants showed homotypic aggregation in suspension culture. Analysis of integrin expression revealed that LFA-1 appeared to be expressed on CD21 transfectants, and the cell aggregation was abrogated by anti-LFA-1 antibody. The CD21 transfectants could adhere to plastic plates coated with ICAM-1. Moreover, flow cytometry and/or immunohistochemical analyses of clinical BCL samples (n = 29) revealed positive for CD21 in all cases; LFA-1 was also expressed without exception. All BCL cells isolated from cavity fluids (n = 10) failed to express both CD21 and LFA-1. These data suggest that CD21 is tightly related to LFA-1 expression in BCL and the absence of CD21/LFA-1 expression is associated with pleural/peritoneal fluid involvement by BCL, a potential indicator of disease progression of BCL.
Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Ehime, 791-0295, Japan.
Kazushi
K
Tanimoto
Cancer Center, Ehime University Graduate School of Medicine, Toon, Ehime, 791-0295, Japan. yoshiyak@m.ehime-u.ac.jp.
Yoshihiro
Y
Yakushijin
Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Ehime, 791-0295, Japan.
Hiroshi
H
Fujiwara
Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Ehime, 791-0295, Japan.
Masaki
M
Otsuka
Department of Pathology, Kurume University School of Medicine, Fukuoka, Japan.
Koichi
K
Ohshima
Department of Pathology, Ehime University Graduate School of Medicine, Ehime, Japan.
Atsuro
A
Sugita
Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Akira
A
Sakai
Division of Blood Transfusion and Cell Therapy, Ehime University Graduate School of Medicine, Ehime, Japan.
Takaaki
T
Hato
Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Ehime, 791-0295, Japan.
Hitoshi
H
Hasegawa
Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Ehime, 791-0295, Japan. yasukawa@m.ehime-u.ac.jp.
Masaki
M
Yasukawa
D002460:Cell Line; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D016169:Lymphocyte Function-Associated Antigen-1 / Q000235:genetics / Q000378:metabolism*; D016393:Lymphoma, B-Cell / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D017464:Receptors, Complement 3d / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D014158:Transcription, Genetic / Q000235:genetics
D016169:Lymphocyte Function-Associated Antigen-1; D017464:Receptors, Complement 3d; D018799:Intercellular Adhesion Molecule-1